BACKGROUND: Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: This randomized, double-blind, multicenter, phase II trial evaluated sunitinib 37.5 mg/day plus erlotinib 150 mg/day versus placebo plus erlotinib continuously in 4-week cycles. Eligible patients had histologically confirmed stage IIIB or IV NSCLC previously treated with one or two chemotherapy regimens, including one platinum-based regimen. The primary end point was progression-free survival (PFS) by an independent central review. RESULTS:One hundred and thirty-two patients were randomly assigned, and the median duration of follow-up was 17.7 months. The median PFS was 2.8 versus 2.0 months for the combination versus erlotinib alone (HR 0.898, P = 0.321). The median overall survival (OS) was 8.2 versus 7.6 months (HR 1.066, P = 0.617). Objective response rates (ORRs) were 4.6% and 3.0%, respectively. Sunitinib plus erlotinib was fairly well tolerated although most treatment-related adverse events (AEs) were more frequent than with erlotinib alone: diarrhea (55% versus 33%), rash (41% versus 30%), fatigue (31% versus 25%), decreased appetite (30% versus 13%), nausea (28% versus 14%), and thrombocytopenia (13% versus 0%). CONCLUSIONS: The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC.
RCT Entities:
BACKGROUND: Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in platinum-pretreated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: This randomized, double-blind, multicenter, phase II trial evaluated sunitinib 37.5 mg/day plus erlotinib 150 mg/day versus placebo plus erlotinib continuously in 4-week cycles. Eligible patients had histologically confirmed stage IIIB or IV NSCLC previously treated with one or two chemotherapy regimens, including one platinum-based regimen. The primary end point was progression-free survival (PFS) by an independent central review. RESULTS: One hundred and thirty-two patients were randomly assigned, and the median duration of follow-up was 17.7 months. The median PFS was 2.8 versus 2.0 months for the combination versus erlotinib alone (HR 0.898, P = 0.321). The median overall survival (OS) was 8.2 versus 7.6 months (HR 1.066, P = 0.617). Objective response rates (ORRs) were 4.6% and 3.0%, respectively. Sunitinib plus erlotinib was fairly well tolerated although most treatment-related adverse events (AEs) were more frequent than with erlotinib alone: diarrhea (55% versus 33%), rash (41% versus 30%), fatigue (31% versus 25%), decreased appetite (30% versus 13%), nausea (28% versus 14%), and thrombocytopenia (13% versus 0%). CONCLUSIONS: The addition of sunitinib to erlotinib did not significantly improve PFS in patients with advanced, platinum-pretreated NSCLC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Roy S Herbst; David H Johnson; Eric Mininberg; David P Carbone; Ted Henderson; Edward S Kim; George Blumenschein; Jack J Lee; Diane D Liu; Mylene T Truong; Waun K Hong; Hai Tran; Anne Tsao; Dong Xie; David A Ramies; Robert Mass; Somasekar Seshagiri; David A Eberhard; Sean K Kelley; Alan Sandler Journal: J Clin Oncol Date: 2005-03-07 Impact factor: 44.544
Authors: Alex H Ramos; Amit Dutt; Craig Mermel; Sven Perner; Jeonghee Cho; Christopher J Lafargue; Laura A Johnson; Ann-Cathrin Stiedl; Kumiko E Tanaka; Adam J Bass; Jordi Barretina; Barbara A Weir; Rameen Beroukhim; Roman K Thomas; John D Minna; Lucian R Chirieac; Neal I Lindeman; Thomas Giordano; David G Beer; Patrick Wagner; Ignacio I Wistuba; Mark A Rubin; Matthew Meyerson Journal: Cancer Biol Ther Date: 2009-11-07 Impact factor: 4.742
Authors: Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer Journal: Clin Exp Metastasis Date: 2003 Impact factor: 5.150
Authors: Roy S Herbst; Vincent J O'Neill; Louis Fehrenbacher; Chandra P Belani; Philip D Bonomi; Lowell Hart; Ostap Melnyk; David Ramies; Ming Lin; Alan Sandler Journal: J Clin Oncol Date: 2007-10-01 Impact factor: 44.544
Authors: Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S Kim; Magaly Zappa; Silvana Lanzalone; Xun Lin; Samuel Deprimo; Charles Harmon; Ana Ruiz-Garcia; Maria J Lechuga; Ann Lii Cheng Journal: Lancet Oncol Date: 2009-07-06 Impact factor: 41.316
Authors: Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson Journal: Lancet Oncol Date: 2010-07 Impact factor: 41.316
Authors: Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer Journal: J Transl Med Date: 2007-07-02 Impact factor: 5.531